CN101899082B - Triterpenoid saponin compound, application and preparation method - Google Patents
Triterpenoid saponin compound, application and preparation method Download PDFInfo
- Publication number
- CN101899082B CN101899082B CN201010234072A CN201010234072A CN101899082B CN 101899082 B CN101899082 B CN 101899082B CN 201010234072 A CN201010234072 A CN 201010234072A CN 201010234072 A CN201010234072 A CN 201010234072A CN 101899082 B CN101899082 B CN 101899082B
- Authority
- CN
- China
- Prior art keywords
- compound
- phaseoloideside
- water
- column chromatography
- gradient elution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Steroid Compounds (AREA)
Abstract
The invention provides triterpenoid saponin compounds, applications and preparation methods, relating to a compound Phaseoloideside D and a compound Phaseoloideside E obtained by separating from mimosoideae entada phaseoloides leguminous plants and medical applications as well as preparation methods thereof. The in-vitro anti-tumor experiment indicates that the compound Phaseoloideside D and the compound Phaseoloideside E have stronger inhibiting effect on SHG-44 (human glioma), SW480 (colon cancer cells), HepG-2 (liver cancer cells), Ec-109 (esophageal cancer cells) and MCF-7 (human breast cancer cells), can provide a leading compound for preparing new antineoplastics and has key value to develop and use medicinal resources in China.
Description
Technical field
The present invention relates to triterpene saponin componds, purposes and preparation method, be specifically related to from leguminous plants Touch-me-notAction Plant Ya Ke Ke Teng Shu Ke vine, separate Compound P haseoloideside D, Phaseoloideside E and medicinal use and the preparation method who obtains.
Background technology
Ke vine (Entada phaseoloides (Linn.) Merr.) belongs to pulse family Touch-me-notAction Plant Ya Ke Ke Calamus, evergreen wooden big liana, and stem is twisted, and branch does not have hair; Two times pinnately compound leaves, long 10-25cm has 2 pairs of accessory pinnas usually, and the top is given birth to a pair of accessory pinna and is become tendril; Leaflet 2-4 is right, keratin, and oblong, long 3-8.5cm, wide 1.5-4cm, tip is blunt, nick, base portion is deflection slightly, does not have hair.Mainly be distributed in ground such as China Fujian, Guangxi, Yunnan, it mainly contains has Ke rattan amides, triterpenoid saponin constituents, has the effect of treatment stomach trouble, hemorrhoid, constipation etc.
The triterpenoid saponin constituents that is contained in the Ke vine congener of following bibliographical information has certain anti-tumor activity: Laurence KN; Luciano B; Remy BT et al.Rheediinosides A and B; Two antiproliferativeand antioxidant triterpene saponins from Entada rheedii.Phytochemistry.2010,71:254-261; Giuseppina C, Fabrizio D P, Paolo De C, et al.Antiproliferative TriterpeneSaponins from Entada africana J.Nat.Prod.2006,69,1323-1329.; Azefack L T, TomofumiM, Mirjolet, J F.Pursaethosides A-E, Triterpene Saponins from Entada pursaetha.J.Nat.Prod.2005,68,1185-1190.
The total saponins thing that contains in the Ke vine also has the obvious suppression effect to mouse S180 solid tumor; Can obviously prolong the restraining effect of ehrlich ascites tumor mouse survival time Ke vine water soluble extract, Xu Teng etc., Chinese pharmacist to mice-transplanted tumor S180; 2006,9 (5): 397-399); Ke vine water soluble extract also has the extracorporeal anti-tumor function of stronger restraining effect ianthone Ke vine water soluble extract to human chronic myelogenous leukemia cell strain (K562), human lymphoma cell strain (U937) and human promyelocytic leukemia cell strain (HL60); Xu Teng etc.; The West China pharmaceutical journal; 2005,20 (6): 487-489).
People's " Ke vine sulfur-bearing amides The Chemical Constituents " such as the south of plum, Xiong Hui; " Acta Pharmaceutica Sinica " 2010; 45 (5): 624-626) disclose and utilize positive reversed-phase silica gel column chromatography, preparation HPLC to divide chemical ingredients from pureization Ke vine kind benevolence; Obtain 4 sulfur-bearing amidess from the n-butanol extraction position separation of 70% ethanol extraction, be respectively entadamide A-β-D-glucopyranosyl-(1 → 3)-β-D-glucopyranoside (1), entadamide A (2), entadamide A-β-Dglucopyranoside (3) and clinacoside C (4).People such as Zhang Yong " Ke vine kind Renhua composition Study "; The 43rd the 14th phase of volume of " Chinese Pharmaceutical Journal " July in 2008) discloses through separation purifying such as Sephadex LH-20; Measure with modern Wave Spectrum technology through physicochemical constant and to carry out after structure identifies, separation obtaining 8 compounds, is respectively 2; 5-dihydroxyphenyl acetic acid ethyl ester, 2,5-dihydroxyphenyl acetic acid methyl esters, 5-hydroxyl-cumarone-2 Tong 、 Ke rattan acid amides A, methyl stearate, β-Gu Zaichun, daucosterol and Stigmasterol.Chinese patent CN 101486650A discloses and a kind ofly from beans section Ke rattan platymiscium Ke rattan, has prepared 2; 5-dihydroxyphenyl acetic acid ethyl ester, 2; 5-dihydroxyphenyl acetic acid methyl esters, 2, the method for the positive butyl ester of 5-dihydroxyphenyl acetic acid, and the application of these compounds in the preparation inverase.
Yet, also do not have the researchist to report saponins compound Phaseoloideside D and Phaseoloideside E contained in the You Guan Ke vine at present.
Summary of the invention
One of the object of the invention provides Compound P haseoloideside D, the Phaseoloideside E that separation obtains from leguminous plants Touch-me-notAction Plant Ya Ke Ke Teng Shu Ke vine.
The contriver from grow in Chinese yunnan Xishuangbanna area De Ke vine kind benevolence extraction separation to two kinds of new saponins compounds, called after Phaseoloideside D respectively:
3-O-β-D-glucopyranosyl-(1→4)-[β-D-xylopyranosyl-(1→3)-α-L-arabinopyranosyl-(1→6)]-2-acetylamino-2-deoxy-β-D-glucopyranosylentagenic?acid28-O-β-D-apiofuranosyl-(1→5)-O-β-D-apiofuranosyl-(1→2)-2-acetyl-2-deoxy-O-β-D-glucopyranoside；
With Phaseoloideside E:
3-O-β-D-glucopyranosyl-(1→4)-[β-D-xylopyranosyl-(1→3)-α-L-arabinopyranosyl-(1→6)]-2-acetylamino-2-deoxy-β-D-glucopyranosylentagenic?acid28-O-β-D-apiofuranosyl-(1→3)-O-β-D-xylopyranosyl-(1→2)-2-acetyl-2-deoxy-O-β-D-glucopyranoside。
Its chemical structure is following:
Two of the object of the invention is open Phaseoloideside D or the application of Phaseoloideside E in the preparation antitumor drug.
The contriver confirms through experiment in vitro; Phaseoloideside D demonstrates the obvious suppression effect to SHG-44 (human glioma cell), SW480 (colon cancer cell), HepG-2 (liver cancer cell), Ec-109 (esophageal cancer cell), MCF-7 (human breast cancer cell), and Phaseoloideside E demonstrates the obvious suppression effect to JEG-3 SHG-44, SW480, HepG-2.It is thus clear that triterpene saponin componds Phaseoloideside D of the present invention and Phaseoloideside E have the effect of obvious suppression tumour.
The method of extraction separation Phaseoloideside D, Phaseoloideside E in the three Shi Ti Gong Ke vines of the object of the invention.
After the contriver gropes through a large amount of tests, two kinds of methods of extraction separation Phaseoloideside D, Phaseoloideside E have efficiently been obtained.
The step of first kind of method for preparing Compound P haseoloideside D, Phaseoloideside E is following:
(1) preparation total saponin extracts: pulverizes the oven dry of Ke vine kind benevolence dry product, the ethanol room temperature lixiviate with 60～70% 3～7 times, and each 24h, concentrated extracting solution gets medicinal extract; The use volume ratio is 9: 1 a methanol-water solution dissolving medicinal extract; After extracting successively with isopyknic sherwood oil, ETHYLE ACETATE, propyl carbinol, with n-butyl alcohol extract, through silica gel column chromatography; Separate with methylene chloride-methanol solution gradient wash-out; Collect elutriant, decompression and solvent recovery gets total saponin extracts;
(2) separate: with the above-mentioned total saponin extracts applying silicon plastic column chromatography that contains, with ETHYLE ACETATE: methyl alcohol be the eluent gradient elution, and collection contains stream part of triterpenoid saponin; Again through the ODS column chromatography; With methyl alcohol: water is that eluent carries out gradient elution, collects stream part of said compound, again through silica gel column chromatography; With chloroform: methyl alcohol is that eluent carries out gradient elution; Collect stream part of said compound, separate through half preparative high-performance liquid chromatographic method, with acetonitrile: 2.8: 7.2 moving phase of the volume ratio of water is carried out wash-out; Collection contains the flow point of Phaseoloideside D, Phaseoloideside E, reclaims solvent and promptly gets said compound pure article Phaseoloideside D and Phaseoloideside E.Through the various modern spectroscopic analysis, chemical structure and the steric configuration of Phaseoloideside D and Phaseoloideside E have been confirmed in the particularly parsing of the multiple advanced person's of integrated application two NMR spectrums.
The step of second kind of method for preparing Compound P haseoloideside D, Phaseoloideside E is following:
(1) pulverizes Ke vine kind benevolence dry product oven dry, with the ethanol room temperature lixiviate of 60-70% 3-7 time, and 24h at every turn, concentrated extracting solution; Use petroleum ether degreasing then, the medicinal extract of degreasing is redissolved through n-butanol extraction, ethanol, after the vacuum-drying; Be dissolved in methanol-water solution again,, use the ethanol-water solution gradient elution through macroporous resin; Collect elutriant, decompression recycling ethanol gets total saponin extracts;
(2) separate: the above-mentioned total saponin extracts applying silicon plastic column chromatography that contains; With the ethyl acetate, alcohol and water is the eluent gradient elution, collects the stream part that contains triterpenoid saponin, again through the ODS column chromatography; With methyl alcohol: water is that eluent carries out gradient elution; Collection contains stream part of said compound, separates through half preparative high-performance liquid chromatographic method again, and with acetonitrile: 2.8: 7.2 moving phase of the volume ratio of water is carried out wash-out; Collection contains the flow point of Phaseoloideside D, Phaseoloideside E, reclaims solvent and promptly gets said compound pure article Phaseoloideside D and Phaseoloideside E.Through the various modern spectroscopic analysis, chemical structure and the steric configuration of Phaseoloideside D and Phaseoloideside E have been confirmed in the particularly parsing of the multiple advanced person's of integrated application two NMR spectrums.
Compound disclosed by the invention can be used as the lead compound of antitumor drug, for developing new antitumor drug a kind of new thinking is provided, and is significant to the national resources of medicinal plant that develops China.
Embodiment
Below further describe the present invention through preferred embodiment, yet the scope of the invention is not limited only to the following example.Every do not deviate from the change of the present invention design or be equal to substitute include within protection scope of the present invention.
The preparation of embodiment 1 triterpene saponin componds Phaseoloideside D and Phaseoloideside E
1, extraction separation and purification process
Jiang the Gan Zao Ke vine medicinal material De Ke vine benevolence of shelling, dry, pulverize 8000 grams of weighing, extract 3 times with the ethanol soaking at room temperature of 4 times of amounts 70% again, each 24h with the leaching liquid concentrating under reduced pressure, gets translucent medicinal extract 518g.The use volume ratio is 9: 1 a methanol-water mixed solvent dissolving medicinal extract; Extract repeatedly with isopyknic sherwood oil; Colourless basically to petroleum ether layer, medicinal extract is soluble in water, and it is colourless basically to be extracted to ethyl acetate layer repeatedly with isopyknic ETHYLE ACETATE; It is colourless basically to be extracted to n-butanol layer repeatedly with isopyknic propyl carbinol again, merges n-butanol layer and concentrating under reduced pressure and gets translucent mobile medicinal extract 129g.And with n-butanol portion as main separate part, carry out silica gel column chromatography, select for use methylene chloride-methanol to carry out gradient elution, collect the elutriant that contains saponin(e, decompression and solvent recovery must contain total saponin extracts 38.15 grams.To contain total saponins and carry out silica gel column chromatography, with ETHYLE ACETATE: methyl alcohol is the eluent wash-out, collects the elutriant that contains triterpenoid saponin, and decompression and solvent recovery gets triterpenoid saponin 18.59 grams.This triterpenoid saponin is carried out the ODS column chromatography; With methyl alcohol: water is that eluent carries out gradient elution, collects the stream part that contains Compound P haseoloideside D and Phaseoloideside E, again through silica gel column chromatography; With chloroform: methyl alcohol is that eluent carries out gradient elution; Collect stream part of Compound P haseoloideside D and Phaseoloideside E, after half preparative high-performance liquid chromatographic method is separated, with acetonitrile: 2.8: 7.2 moving phase of the volume ratio of water is carried out wash-out; Promptly get pure article 0.3 gram of Phaseoloideside D, pure article 0.35 gram of Phaseoloideside E.
2, compound structure is identified
Phaseoloideside D is white amorphous powder, and Lieberman-Burchard reaction and Molish reaction are all positive through measuring molecular formula C
72H
115NO
37, [α]
D 20-41 (c 0.63, MeOH), and FAB-MS m/z 1586 [M-1]
-, 1453 [M-132-1]
-, 1423 [M-162-1]
-, 1321 [M-132-132-1]
-, 1117 [M-162-132-132-42-1]
-HR ESI-MS provides quasi-molecular ion peak m/z 1608.7082 [M+Na]
+(Calc Mass 1608.7040).
The structural formula of Phaseoloideside D is following:
Phaseoloideside D's
1H-NMR,
13C-NMR and HMBC data such as table 1.
Table 1 Phaseoloideside D's
1H-NMR,
13C-NMR and HMBC data (in C
5D
5N, δ ppm)
Phaseoloideside E is white amorphous powder, and Lieberman-Burchard reaction and Molish reaction are all positive through measuring molecular formula C
72H
115NO
37, [α]
D 20-41 (c 0.63, MeOH), and FAB-MS m/z 1586 [M-1]
-, 1453 [M-132-1]
-, 1423 [M-162-1]
-, 1321 [M-132-132-1]
-, 1117 [M-162-132-132-42-1]
-HR ESI-MS provides quasi-molecular ion peak m/z 1608.7019 [M+Na]
+(Calc Mass 1608.7040).
The structural formula of Phaseoloideside E is following:
Phaseoloideside E's
1H-NMR,
13C-NMR and HMBC data such as table 2.
Table 2 Phaseoloideside E's
1H-NMR,
13C-NMR and HMBC data (in C
5D
5N, δ ppm)
The preparation of embodiment 2 triterpene saponin componds Phaseoloideside D and Phaseoloideside E
Ke vine kind benevolence is dried, pulverize 10000 grams of weighing, with 70% ethanol room temperature lixiviate of 5 times of amounts 7 times, 24h at every turn; Concentrated extracting solution, and then use petroleum ether degreasing, with the medicinal extract of degreasing behind n-butanol extraction, with dissolving in alcoholic acid water layer composition; After vacuum-drying (dry weight 345 gram), be dissolved in volume ratio again and be 9: 1 methanol-water solution, through macroporous resin, water and ethanol gradient elution; Collect 50% ethanol eluate, decompression recycling ethanol gets total saponin extracts 61.61 grams.Total saponin extracts applying silicon plastic column chromatography; With ETHYLE ACETATE: methyl alcohol: water is the eluent gradient elution, collects the stream part that contains this triterpenoid saponin, through the ODS column chromatography; With methyl alcohol: water is that eluent carries out gradient elution; Collection contains stream part of Compound P haseoloideside D and Phaseoloideside E, separates through half preparative high-performance liquid chromatographic method again, and with acetonitrile: 2.8: 7.2 moving phase of the volume ratio of water is carried out wash-out; Promptly get about 0.5 gram of the pure article of Phaseoloideside D, about 0.55 gram of the pure article of Phaseoloideside E.
Embodiment 3Phaseoloideside D and Phaseoloideside E are to the influence of tumour cell
Testing used cell strain is international tumor cell line, that is: SHG-44 (human glioma cell), SW480 (colon cancer cell), HepG-2 (liver cancer cell), Ec-109 (esophageal cancer cell), MCF-7 (human breast cancer cell).
Phaseoloideside D and Phaseoloideside E are to cancer cells cytodifferentiation inducing action---the mtt assay of vitro culture: its principle is that the succinodehydrogenase in the viable cell plastosome can make exogenous MTT be reduced to water-insoluble bluish voilet crystallization first a ceremonial jade-ladle, used in libation (Formazan) and is deposited in the cell, and dead cell does not have this function.First a ceremonial jade-ladle, used in libation in DMSO 99.8MIN. (DMSO) the ability dissolved cell; Measure its absorbance value with enzyme-linked immunosorbent assay instrument in the 492nm wavelength; Can obtain the cancer cells number change of cancer therapy drug effect, once obtain the survival rate of cell, judge the sensitivity of cell anticarcinogen by IC50.According to cell growth rate, the tumour cell that will be in the growth logarithmic phase is inoculated in 96 orifice plates with 100 μ l/ holes, and adherent growth 24h inhales and goes to add 100 μ l/ holes after the supernatant.Each concentration is established 6 multiple holes, and establishes substratum contrast and the acellular zeroing hole that does not add soup.Tumour cell is at 37 ℃, 5%CO
2Cultivated 24 hours in the incubator, every then hole adds 10 μ l MTT, continues to cultivate 4h in the incubator, takes out, and inhales and removes supernatant, adds DMSO 150 μ l/ holes, and ELIASA 492nm wavelength is surveyed the 0D value down, and experimental result is seen table 3:
Table 3 Phaseoloideside D is to the restraining effect IC50 (μ M) of tumour cell
IC50: the half effective inhibition concentration of expression The compounds of this invention
Above-mentioned experimental result shows that Phaseoloideside D shows the obvious suppression effect to SHG-44, SW480, HepG-2, Ec-109, MCF-7, and Phaseoloideside E shows the obvious suppression effect to SHG-44, SW480, HepG-2.It is thus clear that triterpene saponin componds Phaseoloideside D of the present invention and Phaseoloideside E have the effect of obvious suppression tumour.
Claims (6)
1. triterpene saponin componds, structural formula is following:
2. triterpene saponin componds, structural formula is following:
3. the application of the described compound of claim 1 in the preparation antitumor drug, described tumour is human glioma, colorectal carcinoma, liver cancer, the esophageal carcinoma, mammary cancer.
4. the application of the described compound of claim 2 in the preparation antitumor drug, described tumour is human glioma, colorectal carcinoma, liver cancer.
5. the preparation method of claim 1 or 2 said compounds comprises the steps:
(1) pulverizes Ke vine kind benevolence dry product oven dry, with the ethanol room temperature lixiviate of 60-70% 3-7 time, and 24h at every turn, concentrated extracting solution gets medicinal extract; The use volume ratio is 9: 1 a methanol-water solution dissolving medicinal extract, after extracting successively with isopyknic sherwood oil, ETHYLE ACETATE, propyl carbinol, n-butyl alcohol extract is passed through silica gel column chromatography; With methylene chloride-methanol solution gradient wash-out; Collect elutriant, decompression and solvent recovery gets total saponin extracts;
(2) with said total saponin extracts applying silicon plastic column chromatography, be the eluent wash-out, collect the stream part that contains triterpenoid saponin with ETHYLE ACETATE-methanol solution; Again through the ODS column chromatography; With the methanol-water is that eluent carries out gradient elution, collects the stream part that contains said compound, again through silica gel column chromatography; With chloroform-methanol solution is that eluent carries out gradient elution; Collect stream part of said compound, separate through half preparative high-performance liquid chromatographic method again, with acetonitrile: 2.8: 7.2 moving phase of the volume ratio of water carry out behind the wash-out said compound.
6. the preparation method of claim 1 or 2 said compounds comprises the steps:
(1) pulverizes Ke vine kind benevolence dry product oven dry, with the ethanol room temperature lixiviate of 60-70% 3-7 time, and 24h at every turn, concentrated extracting solution; Use petroleum ether degreasing then, the medicinal extract of degreasing is redissolved through n-butanol extraction, ethanol, after the vacuum-drying; Be dissolved in methanol-water solution again,, use the ethanol-water solution gradient elution through macroporous resin; Collect elutriant, decompression recycling ethanol gets total saponin extracts;
(2) with above-mentioned total saponin extracts applying silicon plastic column chromatography; With the ethyl acetate, alcohol and water is the eluent gradient elution, collects the stream part that contains triterpenoid saponin, again through the ODS column chromatography; With methyl alcohol: water is that eluent carries out gradient elution; Collection contains stream part of said compound, separate through half preparative high-performance liquid chromatographic method, with acetonitrile: 2.8: 7.2 moving phase of the volume ratio of water carry out behind the wash-out said compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010234072A CN101899082B (en) | 2010-07-22 | 2010-07-22 | Triterpenoid saponin compound, application and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010234072A CN101899082B (en) | 2010-07-22 | 2010-07-22 | Triterpenoid saponin compound, application and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101899082A CN101899082A (en) | 2010-12-01 |
| CN101899082B true CN101899082B (en) | 2012-10-24 |
Family
ID=43225036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010234072A Expired - Fee Related CN101899082B (en) | 2010-07-22 | 2010-07-22 | Triterpenoid saponin compound, application and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101899082B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109364119A (en) * | 2018-12-26 | 2019-02-22 | 浙江大学 | Preparation has the method and application of the total triterpene of hypoglycemic effect from Qingqian Willow leaf |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102649807A (en) * | 2011-02-25 | 2012-08-29 | 苏州宝泽堂医药科技有限公司 | Preparation method of Heteropappus altaicus saponin (I) |
| CN102229640B (en) * | 2011-06-30 | 2014-04-23 | 中国人民解放军第四军医大学 | Application of triterpenoid saponins compound extracted from anemone taipaiensis |
| CN102488095B (en) * | 2011-12-23 | 2013-02-27 | 重庆优宝生物技术有限公司 | Green feedstuff additive containing camellia seed triterpenoid saponin |
| FR3080044B1 (en) * | 2018-04-12 | 2020-05-01 | Exsymol | PROCESS FOR PRODUCING AN ENTRY OF ENTADA SEED ENRICHED IN METABOLITES OF INTEREST, EXTRACT OBTAINED BY SUCH A PROCESS AND COSMETIC AND DERMOCOSMETIC APPLICATIONS OF SUCH AN EXTRACT |
| CN115651055B (en) * | 2022-10-31 | 2024-03-29 | 上海市奉贤区中心医院 | Oleanane type triterpene saponin compound, and preparation method and application thereof |
-
2010
- 2010-07-22 CN CN201010234072A patent/CN101899082B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109364119A (en) * | 2018-12-26 | 2019-02-22 | 浙江大学 | Preparation has the method and application of the total triterpene of hypoglycemic effect from Qingqian Willow leaf |
| CN109364119B (en) * | 2018-12-26 | 2021-10-01 | 浙江大学 | Method for preparing total triterpenoids with blood sugar reducing effect from cyclocarya paliurus leaves and application of total triterpenoids |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101899082A (en) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101899082B (en) | Triterpenoid saponin compound, application and preparation method | |
| Li et al. | Lignans from the heartwood of Streblus asper and their inhibiting activities to hepatitis B virus | |
| CN101190258A (en) | Total sesquiterpene lactone extract containing rich parthenolide and preparation method and application thereof | |
| CN103665082B (en) | Hemsleya cucurbitane tetracyclic triterpenoid compound, pharmaceutical compositions containing same and application of compound and pharmaceutical composition | |
| Syarifah et al. | Potential anticancer compound from Cerbera odollam | |
| CN106008502B (en) | Purslane middle skeleton alkaloid compound and its extraction separation method | |
| CN104817432A (en) | Anti-tumor drug of diterpenoid compound, and preparation method and application thereof | |
| CN103626824B (en) | Hemsleya amabilis cucurbitane tetracyclic triterpene compound, pharmaceutical composition comprising compound and application of pharmaceutical composition and compound | |
| KR101304997B1 (en) | Pharmaceutical compositions for prevention and treatment of cancer diseases containing the fruits of acanthopanax sessiliflorus extracts, fractions, the isolated compounds therefrom, or the pharmaceutically acceptable salts as an active ingredient | |
| Wang et al. | Anticancer, antioxidant, and antimicrobial activities of anemone (Anemone cathayensis) | |
| CN104892713A (en) | Preparation method and applications of cucurbitacin C and analogs thereof | |
| CN112898357B (en) | Diterpene glycoside novel compound in trollius chinensis bunge and separation and purification method and application thereof | |
| CN102462727A (en) | Yulangsan general flavone and action of monomer component thereof in preparation of anti-tumor medicament | |
| CN101190259A (en) | Southern magnolia total lactone extract and preparation method and application thereof | |
| CN102764320B (en) | Psychotria sp. extract, and preparation method and antineoplastic application thereof | |
| WO2012061954A1 (en) | Preparative method and use of zingiberensis saponin extracted from dioscorea zingiberensis with antitumor activity | |
| CN104788291B (en) | The antitumor drug and method for application of the detached diterpene-kind compound of Flos Rhododendri Mollis | |
| CN103027932A (en) | Cortex periplocae anti-tumor effective component extractive as well as preparation method and application thereof | |
| CN110540530B (en) | Chicken bone vetiver extract and supercritical fluid extraction method and application thereof | |
| CN114605422A (en) | A pair of enantiomer alkaloid dimer compounds, and preparation method and application thereof | |
| CN101468950B (en) | Novel compound separated from immature exocarp of Juglans mandshurica Maxim, and preparation and use thereof | |
| CN106810551A (en) | Two kinds of new carbon skeleton alkaloid compounds and its extraction separation method | |
| RU2776898C1 (en) | Method for producing myricitrin from the bark of eastern black walnut, exhibiting neurotropic activity | |
| CN111171100B (en) | Limonin compound with anti-tumor activity and preparation method thereof | |
| CN105777839B (en) | A kind of antitumoral compounds, its extracting method and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121024 Termination date: 20210722 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |